Date of Award
Spring 2021
Degree Type
Thesis
Department
College of Pharmacy
Director of Thesis
Eugenia Broude, PhD
First Reader
Zachary Mack
Second Reader
Zachary Mack
Abstract
Cyclin-dependent kinases (CDK) 4 and 6 are the main drivers of proliferation in estrogen receptor (ER)-positive breast cancer cells. CDK4/6 inhibitors, such as the FDA-approved cytostatic drug, Palbociclib, induce G1 arrest and prevent cell cycle progression. Prolonged treatment with CDK4/6 inhibitors can lead to drug resistance in the clinic as well as in the lab. The mechanisms behind this resistance are varied, with preliminary evidence suggesting that it may be influenced by the senescence-associated secretory phenotype (SASP), CDK6 hyperactivation, or degradation of the retinoblastoma protein (Rb). In contrast to the cell cycle mediating CDK4/6, CDK8 and 19 are involved in regulating transcription. CDK8/19 phosphorylate the C-terminal domain (CTD) of RNA polymerase II (Pol II), inducing the elongation of transcription. Studies have shown that high CDK8/19 expression is associated with shorter relapse-free survival and failure of systemic therapy in breast cancer. Preliminary data suggest the inhibition of CDK8/19 successfully prevents resistance to CDK4/6 inhibitors, resulting in complete elimination of cancer cells. This project will help establish why combination therapy with CDK8/19 inhibitors prevents drug resistance to CDK4/6 inhibitors via the suppression of ER-regulated transcription of mitogenic factors. This drug combination therapy may have clinical relevance for preventing drug resistance in ER-positive breast cancer.
First Page
1
Last Page
15
Recommended Citation
Safa, Samantha Tolentino, "Combination Treatment with CDK4/6 and CDK8/19 Inhibitors in ER-positive Breast Cancer" (2021). Senior Theses. 461.
https://scholarcommons.sc.edu/senior_theses/461
Rights
© 2021, Samantha Tolentino Safa